{"id":410154,"date":"2021-01-07T07:03:12","date_gmt":"2021-01-07T12:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410154"},"modified":"2021-01-07T07:03:12","modified_gmt":"2021-01-07T12:03:12","slug":"biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/","title":{"rendered":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc.<\/a> (Nasdaq:\u00a0BCRX) today announced that the compensation committee of BioCryst\u2019s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

The options have an exercise price of\u00a0$7.45 per share, which is equal to the closing price of BioCryst common stock on the grant date.\u00a0The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee\u2019s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of BioCryst\u2019s Inducement Equity Incentive Plan and a stock option agreement covering the grant.<\/p>\n

\n About BioCryst Pharmaceuticals <\/strong>\n <\/p>\n

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO\u2122 (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB\u00ae<\/sup> (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company\u2019s website at www.biocryst.com.<\/p>\n

BCRXW<\/p>\n

\n
\n Investor Contact:<\/u>
\n <\/strong>
\n
John Bluth
+1 919 859 7910
jbluth@biocryst.com<\/a><\/p>\n

\n
\n Media Contact:<\/u>
\n <\/strong>
\n
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the compensation committee of BioCryst\u2019s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of\u00a0$7.45 per share, which is equal to the closing price of BioCryst common stock on the grant date.\u00a0The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee\u2019s continued service with the … <\/p>\n

Continue reading “BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410154","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the compensation committee of BioCryst\u2019s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of\u00a0$7.45 per share, which is equal to the closing price of BioCryst common stock on the grant date.\u00a0The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee\u2019s continued service with the … Continue reading "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T12:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-01-07T12:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/\"},\"wordCount\":333,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/\",\"name\":\"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=\",\"datePublished\":\"2021-01-07T12:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/","og_locale":"en_US","og_type":"article","og_title":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the compensation committee of BioCryst\u2019s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of\u00a0$7.45 per share, which is equal to the closing price of BioCryst common stock on the grant date.\u00a0The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee\u2019s continued service with the … Continue reading \"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T12:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-01-07T12:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/"},"wordCount":333,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/","name":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=","datePublished":"2021-01-07T12:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUxMCMzOTA1ODEyIzIwMDQ3MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410154"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410154\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}